Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantern Pharma Inc. (LTRN) on April 26, 2022, covering events occurring on April 20, 2022, and April 26, 2022. The filing addresses changes to the Company's Board of Directors ahead of the Annual Meeting of Stockholders scheduled for June 8, 2022.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
- Director Departure: Leslie W. Kreis, Jr. notified the Company on April 20, 2022, that he will not stand for reelection to the Board of Directors.
- Director Nomination: On April 26, 2022, the Board named Maria L. Maccecchini, Ph.D., as a nominee for election to the Board of Directors.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of operational risks. It notes that the report may be deemed solicitation material for the 2022 Annual Meeting. Investors are urged to read the definitive proxy statement for important information regarding the Company, the Annual Meeting, and the interests of directors and executive officers.
Key Facts for Investor Verification
- Verify the election results for Maria L. Maccecchini, Ph.D., at the June 8, 2022, Annual Meeting.
- Review the definitive proxy statement for details on the composition of the Board and potential conflicts of interest.
- Confirm the effective date of Leslie W. Kreis, Jr.'s departure from the Board.